What Changes Monday Morning? | Practice Applications in Breast Cancer | HER2+ Disease

What Changes Monday Morning? | Practice Applications in Breast Cancer | ER+ DiseaseПодробнее

2021 SABCS What Changes Monday Morning? HER2+ Breast Cancer Panel DiscussionПодробнее

What Changes Monday Morning? | Practice Applications in Breast Cancer | Metastatic DiseaseПодробнее

What Changes Monday Morning? | Practice Applications in Breast Cancer | Triple Negative DiseaseПодробнее

2021 SABCS What Changes Monday Morning? ER+ Breast Cancer Panel DiscussionПодробнее

T-DM1 as part of our standard of care with residual HER 2+ diseaseПодробнее

2023 What Changes Monday Morning? | ESMO Breast Cancer WebinarПодробнее

What Changes Monday Morning? | Post ASCO21 Breast Cancer PanelПодробнее

APHINITY Update - Pertuzumab in HER2+ breast cancerПодробнее

Picking the right CDK 4/6 inhibitor upfront for metastatic breast cancer.Подробнее

2021 SABCS What Changes Monday Morning? Metastatic Breast Cancer Panel DiscussionПодробнее

Monday Morning Practice Implications: Q&A and Case Discussion #1Подробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer HighlightsПодробнее

Breast Cancer update - WebinarПодробнее

2022 KU Post San Antonio Review | Monday Morning Practice Implications: Q&A and Case Discussion 2Подробнее

2021 SABCS What Changes Monday Morning? Triple-Negative Breast Cancer Panel DiscussionПодробнее

2022 KU Post San Antonio Review | Monday Morning Practice Implications: Q&A and Case Discussion 1Подробнее